3-(3-cyanophenyl)-n-n-propylpiperidine profile

3-(3-cyanophenyl)-N-n-propylpiperidine: a dopamine autoreceptor antagonist; RN given for (+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5119
CHEMBL ID	107492
SCHEMBL ID	872942
MeSH ID	M0247737

Synonym
150336-90-6
(-)-3-(1-propyl-piperidin-3-yl)-benzonitrile
bdbm50041960
3-(1-propyl-piperidin-3-yl)-benzonitrile
(+)-3-(1-propyl-piperidin-3-yl)-benzonitrile
benzonitrile, 3-(1-propyl-3-piperidinyl)-, (+-)-
ds121 cpd
L007862
CHEMBL107492 ,
3-(1-propyl-3-piperidinyl)benzonitrile
3-(1-propylpiperidin-3-yl)benzonitrile
ds-121
3-(3-cyanophenyl)-n-n-propylpiperidine
SCHEMBL872942
DTXSID40933909
PD161676

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
D(2) dopamine receptor	Bos taurus (cattle)	Ki	1.1830	0.0000	0.5836	6.1000	AID62337; AID62338
D(4) dopamine receptor	Homo sapiens (human)	Ki	0.9330	0.0000	0.4362	10.0000	AID63849
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.6410	0.0000	0.6020	10.0000	AID65135; AID65786
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	3.4924	0.0000	0.4375	10.0000	AID65559; AID65560
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
synaptic transmission, dopaminergic	D(2) dopamine receptor	Bos taurus (cattle)
negative regulation of prolactin secretion	D(2) dopamine receptor	Bos taurus (cattle)
negative regulation of lactation	D(2) dopamine receptor	Bos taurus (cattle)
positive regulation of mammary gland involution	D(2) dopamine receptor	Bos taurus (cattle)
hyaloid vascular plexus regression	D(2) dopamine receptor	Bos taurus (cattle)
positive regulation of MAP kinase activity	D(4) dopamine receptor	Homo sapiens (human)
behavioral fear response	D(4) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(4) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(4) dopamine receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	D(4) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(4) dopamine receptor	Homo sapiens (human)
dopamine receptor signaling pathway	D(4) dopamine receptor	Homo sapiens (human)
adult locomotory behavior	D(4) dopamine receptor	Homo sapiens (human)
positive regulation of sodium:proton antiporter activity	D(4) dopamine receptor	Homo sapiens (human)
positive regulation of kinase activity	D(4) dopamine receptor	Homo sapiens (human)
response to histamine	D(4) dopamine receptor	Homo sapiens (human)
social behavior	D(4) dopamine receptor	Homo sapiens (human)
regulation of dopamine metabolic process	D(4) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(4) dopamine receptor	Homo sapiens (human)
fear response	D(4) dopamine receptor	Homo sapiens (human)
regulation of circadian rhythm	D(4) dopamine receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	D(4) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(4) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(4) dopamine receptor	Homo sapiens (human)
rhythmic process	D(4) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(4) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(4) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(4) dopamine receptor	Homo sapiens (human)
inhibitory postsynaptic potential	D(4) dopamine receptor	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	D(4) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(4) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	D(4) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	D(4) dopamine receptor	Homo sapiens (human)
chemical synaptic transmission	D(4) dopamine receptor	Homo sapiens (human)
response to ethanol	D(3) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(3) dopamine receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
learning or memory	D(3) dopamine receptor	Homo sapiens (human)
learning	D(3) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(3) dopamine receptor	Homo sapiens (human)
visual learning	D(3) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(3) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(3) dopamine receptor	Homo sapiens (human)
response to histamine	D(3) dopamine receptor	Homo sapiens (human)
social behavior	D(3) dopamine receptor	Homo sapiens (human)
response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(3) dopamine receptor	Homo sapiens (human)
response to morphine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of mitotic nuclear division	D(3) dopamine receptor	Homo sapiens (human)
acid secretion	D(3) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of oligodendrocyte differentiation	D(3) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(3) dopamine receptor	Homo sapiens (human)
musculoskeletal movement, spinal reflex action	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(3) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(3) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(3) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(4) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(4) dopamine receptor	Homo sapiens (human)
protein binding	D(4) dopamine receptor	Homo sapiens (human)
potassium channel regulator activity	D(4) dopamine receptor	Homo sapiens (human)
SH3 domain binding	D(4) dopamine receptor	Homo sapiens (human)
dopamine binding	D(4) dopamine receptor	Homo sapiens (human)
identical protein binding	D(4) dopamine receptor	Homo sapiens (human)
metal ion binding	D(4) dopamine receptor	Homo sapiens (human)
epinephrine binding	D(4) dopamine receptor	Homo sapiens (human)
norepinephrine binding	D(4) dopamine receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	D(4) dopamine receptor	Homo sapiens (human)
neurotransmitter receptor activity	D(4) dopamine receptor	Homo sapiens (human)
serotonin binding	D(4) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
Golgi membrane	D(2) dopamine receptor	Bos taurus (cattle)
centrosome	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(4) dopamine receptor	Homo sapiens (human)
membrane	D(4) dopamine receptor	Homo sapiens (human)
postsynapse	D(4) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(4) dopamine receptor	Homo sapiens (human)
dendrite	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay ID	Title	Year	Journal	Article
AID168131	Evaluated for DOPA accumulation in striatum of reserpine pretreated rat at 100 umol / kg administered intraperitoneally	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168318	Evaluated for rat locomotor activity in nonpretreated habituated rats at 100 umol / kg	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID204602	Binding affinity for sigma receptor using 2 nM of [3H]DTG as radioligand, in membranes from brain minus cerebellum	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168030	Rat locomotor activity in reserpine pretreated rats and accumulated counts / 30 min is calculated	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID63849	Binding towards dopamine receptor D4 expressed in CHO-K1 cells using [3H]spiperone	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168124	Evaluated for DOPA accumulation in limbic region of reserpine pretreated rat at 52 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID65559	Evaluated for binding towards Dopamine receptor D2 using [3H]N-0437 as radioligand from rat striatal membrane	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168119	Evaluated for DOPA accumulation in limbic region of nonpretreated rat at 25 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID13531	Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID65786	Binding towards Dopamine receptor D3 expressed in CHO-K1 cells using [3H]spiperone	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID204607	Binding effinity for sigma receptor using 2 nM of [3H]DTG as radioligand, in membranes from brain minus cerebellum	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168000	Evaluated for 5-HTP increase in limbic region of nonpretreated rat at 52 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168004	Evaluated for DOPA accumulation in limbic region of nonpretreated rat at 200 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID197560	Evaluated for rat locomotor activity in nonhabituated rats at 25 umol / kg	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID62337	Binding towards Dopamine receptor D2 expressed in CHO-K1 cells using [3H]U-86170	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID167993	Evaluated for 5-HTP increase in hemisphere region of nonpretreated rat at 100 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168316	Evaluated for rat locomotor activity in nonhabituated rats at 25 umol / kg	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID62338	Evaluated for binding towards Dopamine receptor D2 using [3H]-spiperone as radioligand, in cloned mammalian receptors expressed in CHO-K1 cells	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID167997	Evaluated for 5-HTP increase in limbic region of nonpretreated rat at 100 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168129	Evaluated for DOPA accumulation in striatum of nonpretreated rat at 25 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID65560	Binding towards Dopamine receptor D2 using [3H]spiperone from rat striatal membrane	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168128	Evaluated for DOPA accumulation in striatum of nonpretreated rat at 200 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168120	Evaluated for DOPA accumulation in limbic region of nonpretreated rat at 52 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168125	Evaluated for DOPA accumulation in striatum of nonpretreated rat at 100 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168311	Evaluated for rat locomotor activity in nonhabituated rats at 100 umol / kg	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168001	Evaluated for DOPA accumulation in limbic region of nonpretreated rat at 100 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168130	Evaluated for DOPA accumulation in striatum of nonpretreated rat at 52 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID167998	Evaluated for 5-HTP increase in limbic region of nonpretreated rat at 200 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168659	Evaluated in rat striatum for the effect on DOPAC release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID167995	Evaluated for 5-HTP increase in hemisphere region of nonpretreated rat at 200 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID65135	Compound was measured for its ability to compete with [3H]spiperone binding to the human Dopamine receptor D3 transfected in CHO cells	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach.
AID168314	Evaluated for rat locomotor activity in nonhabituated rats at 200 umol / kg administered subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168655	Evaluated in rat accumbens for the effect on DOPAC release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168660	Evaluated in rat striatum for the effect on dopamine release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168656	Evaluated in rat accumbens for the effect on dopamine release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168320	Evaluated for rat locomotor activity in nonpretreated habituated rats at 25 umol / kg	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (75.00)	18.2507
2000's	2 (25.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	2.4	2	phenols; tertiary amino compound; tetralins	serotonergic antagonist
caffeine [no description available]	1.98	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.01	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2.4	2	primary amine
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.01	1	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.4	2	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.01	1	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
oxatomide oxatomide: structure; an anti-allergic & an anti-asthmatic. oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.	2.01	1	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist
spiperone Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.	2.01	1	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.01	1	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
acetabutone acetabutone: was MH 1976-92 (see under BUTYROPHENONES 1976-90); ACEPERONE was see ACETABUTONE 1976-92; use BUTYROPHENONES to search ACETABUTONE 1976-92	2.01	1
preclamol [no description available]	2.4	2	piperidines
eticlopride eticlopride: blocks dopamine-D2 binding sites; structure given in first source; RN given refers to (S)-isomer	2.01	1	salicylamides
centbutindole centbutindole: RN given refers to cpd without isomeric designation	2.01	1	beta-carbolines
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	1.99	1
s 14297 7-(N,N-dipropylamino)-5,6,7,8-tetrahydronaphtho(2,3-b)dihydro-2,3-furan: S-11566 is the (+-)-isomer; a dopamine D3 receptor antagonist	2.01	1
aj 76 5-methoxy-1-methyl-2-(n-propylamino)tetralin: RN given refers to cis-(+)-isomer; structure given in first source. (1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin : A secondary amino compound that consists of tetralin bearing methyl, propylamino and methoxy groups at positions 1, 2 and 5 respectively. Dopamine receptor antagonist with preferential action at presynaptic receptors (pKi values are 6.95, 6.67, 6.37, 6.21 and 6.07 at hD3. hD4, hD2S, hD2L and rD2 receptors respectively).	2.4	2	secondary amino compound; tetralins	dopaminergic antagonist
5-hydroxy-1-methyl-2--(di-n-propylamino)tetralin methyl ether UH 232: RN given refers to cis-isomer; RN not in Chemline 9/85; RN and structure given in first source	2.4	2
1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine 1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine: RN refers to (R)-isomer; a dopamine autoreceptor agonist; structure given in first source	2.01	1
l 741626 3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source	2.01	1	piperidines
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.91	4	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
raclopride Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.	2.01	1	salicylamides
nafadotride nafadotride: structure given in first source. nafadotride : A naphthalenecarboxamide resulting from the formal condensation of the carboxylic acid group of 4-cyano-1-methoxynaphthalene-2-carboxylic acid with the primary amino group of 1-(1-butylpyrrolidin-2-yl]methanamine. It is a highly potent, competitive, preferential dopamine D3 receptor antagonist, centrally active upon systemic administration.	2.01	1	aromatic ether; naphthalenecarboxamide; nitrile; pyrrolidines; tertiary amino compound	dopaminergic antagonist
7-hydroxy-2-n,n-dipropylaminotetralin, (r)-isomer [no description available]	2.01	1
uh 232 [no description available]	1.98	1	tetralins
piperidines Piperidines: A family of hexahydropyridines.	3.24	6
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.01	1	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic

Condition	Relationship Strength	Studies
Inadequate Sleep [description not available]	1.99	1
Cocaine Abuse [description not available]	2	1
Cocaine-Related Disorders Disorders related or resulting from use of cocaine.	2	1

3-(3-cyanophenyl)-n-n-propylpiperidine

Description

Cross-References

Synonyms (16)

Protein Targets (4)

Inhibition Measurements

Biological Processes (62)

Molecular Functions (14)

Ceullar Components (8)

Bioassays (36)

Research

Studies (8)

Market Indicators

Research Demand Index: 11.97

Study Types

3-(3-cyanophenyl)-n-n-propylpiperidine

Description

Cross-References

Synonyms (16)

Protein Targets (4)

Inhibition Measurements

Biological Processes (62)

Molecular Functions (14)

Ceullar Components (8)

Bioassays (36)

Research

Studies (8)

Market Indicators

Research Demand Index: 11.97

Study Types

Related Drugs (27)

Related Conditions (3)